

AMENDED IN ASSEMBLY AUGUST 21, 2006

AMENDED IN ASSEMBLY AUGUST 8, 2006

AMENDED IN ASSEMBLY AUGUST 7, 2006

AMENDED IN ASSEMBLY JUNE 20, 2006

AMENDED IN SENATE MAY 26, 2006

AMENDED IN SENATE APRIL 26, 2006

AMENDED IN SENATE APRIL 6, 2006

SENATE BILL

No. 1260

Introduced by Senators Ortiz and Runner

February 9, 2006

An act to amend Sections 125118, 125119, 125119.3, 125119.5, and 125300 of, and to add Chapter 2 (commencing with Section 125330) to Part 5.5 of Division 106 of, the Health and Safety Code, relating to reproductive health.

LEGISLATIVE COUNSEL'S DIGEST

SB 1260, as amended, Ortiz. Reproductive health and research.

The California Stem Cell Research and Cures Act, an initiative measure approved by the voters at the November 2, 2004, general election (Proposition 71), establishes the California Institute for Regenerative Medicine, the purpose of which is, among other things, to make grants and loans for stem cell research, for research facilities, and for other vital research opportunities to realize therapies, protocols, and medical procedures that will result in; the cure for, or substantial mitigation of, diseases and injuries. Existing law establishes the Independent Citizen's Oversight Committee (ICOC),

composed of appointed members, that is required to perform various functions and duties with regard to the operation of the institute, including, but not limited to, establishing standards applicable to research funded by the institute.

Existing law prohibits amendment of Proposition 71 by the Legislature unless the amendment is approved by the voters, or the amendment is accomplished by a bill introduced after the first 2 full calendar years and approved by a vote of 70% of both houses.

Existing law, which is not applicable to research funded under Proposition 71, and which would be repealed on January 1, 2007, requires the State Department of Health Services to, among other things, develop guidelines for research involving the derivation or use of embryonic stem cells, and to report annually to the Legislature.

This bill would delete the repeal date of those provisions, thus indefinitely extending their duration. The bill would also revise the department's reporting duties, by requiring biennial *reviews* rather than annual reports to the Legislature.

Existing law requires research projects involving the derivation or use of human embryonic stem cells to be reviewed and approved by an institutional review board established in accordance with federal regulations.

This bill would revise a related declaration of state policy, would require these research projects to instead be reviewed and approved by a stem cell research oversight committee established substantially in accordance with specified guidelines, and would make these provisions applicable also to research projects involving human adult stem cells.

Existing law applicable to fertility treatment requires that a physician and surgeon provide a patient with prescribed information and obtain the patient's informed consent prior to providing the fertility treatment.

This bill, with certain exceptions, would require a physician and surgeon, prior to ~~conducting~~ *obtaining informed consent from a subject for* assisted oocyte production, as defined, or other method of ovarian retrieval for purposes of retrieving eggs for research or for developing medical therapies, to provide the subject with a standardized written summary of health and consumer issues and to obtain the subject's written and oral informed consent for the procedure.

Existing law prohibits a person from knowingly, for valuable consideration, purchasing or selling embryonic or cadaveric fetal tissue for research purposes.

This bill would prohibit human oocytes or embryos from being acquired, sold, offered for sale, received, or otherwise transferred for valuable consideration for medical research or development of medical therapies, and would prohibit payment in excess of the amount of reimbursement of expenses to be made to any research subject to encourage her to produce human oocytes for the purposes of medical research.

The bill would declare that it is not to be construed to amend Proposition 71.

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: no.

The people of the State of California do enact as follows:

1 SECTION 1. The Legislature finds and declares all of the
2 following:

3 (a) The purpose of this act is to create protections for research
4 subjects and it should not be construed to affect any other form
5 of medical care.

6 (b) Scientific research can be most effectively achieved by
7 establishing protocols to protect, respect, and promote human
8 health, safety, dignity, autonomy, and rights in conducting
9 research.

10 (c) This act seeks to support the requirements already in
11 current law upholding the principle of voluntary and informed
12 consent and to tailor them to this new area of pioneering research
13 that utilizes human oocytes.

14 (d) The potential for exploitation of the reproductive
15 capabilities of women for commercial gain raises health and
16 ethical concerns that justify the prohibition of payment for
17 human oocytes.

18 SEC. 2. Section 125118 of the Health and Safety Code is
19 amended to read:

20 125118. (a) ~~The Maternal, Child, and Adolescent Health~~
21 ~~Branch of the~~ State Department of Health Services shall develop
22 guidelines for research involving the derivation or use of human
23 embryonic stem cells in California.

1 (b) In developing the guidelines specified in subdivision (a),
2 the ~~branch~~ department may consider other applicable guidelines
3 developed or in use in the United States and in other countries,
4 including, but not limited to, the Guidelines for Research Using
5 Human Pluripotent Stem Cells developed by the National
6 Institutes of Health and published in August 2000, and corrected
7 in November 2000, and the Guidelines for Human Embryonic
8 Stem Cell Research issued by the National Research Council and
9 Institute of Medicine of the National Academies in 2005.

10 SEC. 3. Section 125119 of the Health and Safety Code is
11 amended to read:

12 125119. (a) (1) All research projects involving the
13 derivation or use of human embryonic stem cells shall be
14 reviewed and approved by a stem cell research oversight
15 committee prior to being undertaken. Any stem cell research
16 oversight committee shall, in its review of human embryonic
17 stem cell research projects, consider and apply the guidelines
18 developed by the department pursuant to Section 125118. A stem
19 cell research oversight committee may require modifications to
20 the plan or design of a proposed human embryonic stem cell
21 research project as a condition of approving the research project.

22 (2) A stem cell research oversight committee for purposes of
23 this article shall be established substantially in accordance with
24 Guidelines for Human Embryonic Stem Cell Research issued by
25 the National Research Council and the Institute of Medicine of
26 the National Academies in 2005. *This committee shall be*
27 *established in accordance with standards issued by the*
28 *California Institute for Regenerative Medicine (CIRM) as*
29 *authorized by Article XXXV of the California Constitution. The*
30 *intent of the Legislature is to avoid inconsistencies for stem cell*
31 *research oversight committees established pursuant to this*
32 *article with other existing standards for research conducted in*
33 *California.*

34 (b) Not less than once per year, a stem cell research oversight
35 committee shall conduct continuing review of human embryonic
36 stem cell research projects reviewed and approved under this
37 section in order to ensure that the research continues to meet the
38 standards for stem cell research oversight committee approval.
39 Pursuant to its review in accordance with this subdivision, a stem
40 cell research oversight committee may revoke its prior approval

1 of research under this section and require modifications to the
2 plan or design of a continuing research project before permitting
3 the research to continue.

4 (c) A stem cell research oversight committee may provide
5 scientific and ethical review of research consistent with this
6 article.

7 SEC. 4. Section 125119.3 of the Health and Safety Code is
8 amended to read:

9 125119.3. (a) Each stem cell research oversight committee
10 that has reviewed human embryonic stem cell research pursuant
11 to Section 125119 shall report to the department, annually, on the
12 number of human embryonic stem cell research projects that the
13 stem cell research oversight committee has reviewed, and the
14 status and disposition of each of those projects, including the
15 information collected pursuant to Section 125342.

16 (b) Each stem cell research oversight committee shall also
17 report to the department regarding unanticipated problems,
18 unforeseen issues, or serious continuing investigator
19 noncompliance with the requirements or determinations of the
20 stem cell research oversight committee with respect to the review
21 of human embryonic stem cell research projects, and the actions
22 taken by the stem cell research oversight committee to respond to
23 these situations.

24 SEC. 5. Section 125119.5 of the Health and Safety Code is
25 amended to read:

26 125119.5. (a) The department shall at least annually review
27 reports from stem cell research oversight committees, and may
28 revise the guidelines developed pursuant to Section 125118, as it
29 deems necessary.

30 (b) The department shall ~~report biennially~~ *provide a biennial*
31 *review* to the Legislature on human embryonic stem cell research
32 activity. These ~~biennial reports~~ *reviews* shall be compiled from
33 the reports from stem cell research oversight committees.

34 SEC. 6. Section 125300 of the Health and Safety Code is
35 amended to read:

36 125300. The policy of the State of California shall be that
37 research involving the derivation and use of human embryonic
38 stem cells, human embryonic germ cells, and human adult stem
39 cells, including somatic cell nuclear transplantation, shall be
40 reviewed by a stem cell research oversight committee.

1 SEC. 7. Chapter 2 (commencing with Section 125330) is
2 added to Part 5.5 of Division 106 of the Health and Safety Code,
3 to read:

4

5 CHAPTER 2. PROCURING OF OOCYTES FOR RESEARCH

6

7 125330. The following definitions shall apply to this chapter:

8 (a) “Assisted oocyte production” or “AOP” means surgical
9 extraction of oocytes following pharmaceutically induced
10 manipulation of oocyte production through the use of ovarian
11 stimulation.

12 (b) “Oocyte” means a female egg or egg cell of a human
13 female.

14 (c) “Subject” means any person undergoing AOP or any
15 alternative method of ovarian retrieval for research or for the
16 development of medical therapies, including those who would
17 not meet the definition of “subject” under 45 C.F.R. 46.102.

18 (d) “Alternate method of oocyte retrieval” means a method of
19 oocyte retrieval that does not involve the pharmaceutically
20 induced manipulation of oocyte production.

21 (e) “Institutional review board” means a body established in
22 accordance with federal regulations, including Part 46
23 (commencing with Section 46.101) of Subchapter A of Subtitle
24 A of Title 45 of the Code of Federal Regulations.

25 125335. (a) ~~conducting~~ *obtaining informed consent*
26 *from a subject for* AOP or any alternative method of ovarian
27 retrieval on a subject for the purpose of procuring oocytes for
28 research or the development of medical therapies, a physician
29 and surgeon shall provide to the subject a standardized medically
30 accurate written summary of health and consumer issues
31 associated with AOP and any alternative methods of oocyte
32 retrieval. The failure to provide to a subject this standardized
33 medically accurate written summary constitutes unprofessional
34 conduct within the meaning of Chapter 5 (commencing with
35 Section 2000) of Division 2 of the Business and Professions
36 Code.

37 (b) The summary shall include, but not be limited to,
38 medically accurate disclosures concerning the potential risks of
39 AOP or any alternative method of oocyte retrieval, including the
40 risks associated with the surgical procedure and with using the

1 drugs, medications, and hormones prescribed for ovarian
2 stimulation during the AOP process or any alternative method of
3 oocyte retrieval.

4 (c) For purposes of subdivision (a), “written summary of
5 health and consumer issues” means the guide published and
6 updated by the American Society for Reproductive Medicine
7 entitled, “Assisted Reproductive Technology: A Guide for
8 Patients” or an alternative written medically accurate document
9 prepared by a recognized authority on oocyte retrieval for
10 medical research that also meets the criteria included in this
11 section. This alternative document may be one that has been
12 approved and recommended by the State Department of Health
13 Services pursuant to Section 125118 and shall include all of the
14 following:

15 (1) The document shall adhere to simplified reading standards,
16 including, but not limited to, those generally accepted and
17 required for government publications. The document shall be
18 written in layperson’s language and shall be made available in
19 languages spoken by subjects in the study if their proficiency is
20 largely in a language other than English. All information in the
21 document shall be conveyed to the subject orally in easy to
22 understand and nontechnical terms.

23 (2) The document shall include additional resources for, or list
24 additional sources of, medical information on health and safety
25 issues surrounding oocyte retrieval.

26 125340. (a) Prior to providing AOP or any alternative
27 method of ovarian retrieval to a subject for the purposes of
28 medical research or development of medical therapies, a
29 physician and surgeon shall obtain written and oral informed
30 consent for the procedure from the subject. Informed consent for
31 the purposes of this chapter shall comply with the informed
32 consent requirements of the Protection of Human Subjects in
33 Medical Experimentation Act (Chapter 1.3 (commencing with
34 Section 24170) of Division 20).

35 (b) The failure to obtain written informed consent from the
36 subject constitutes unprofessional conduct within the meaning of
37 Chapter 5 (commencing with Section 2000) of Division 2 of the
38 Business and Professions Code. Nothing in this section shall be
39 construed to relieve the physician and surgeon from other
40 existing duties under the law, including, but not limited to, the

1 duty to obtain a subject's informed consent after fully explaining
2 the proposed procedure. The requirement that a physician and
3 surgeon provide the standardized written summary pursuant to
4 Section 125335 is in addition to, and does not supplant, other
5 existing legal requirements regarding informed consent,
6 including, but not limited to, compliance with the Protection of
7 Human Subjects in Medical Experimentation Act (Chapter 1.3
8 (commencing with Section 24170) of Division 20.

9 (c) This chapter shall not affect the suitability or availability of
10 oocytes procured for research before January 1, 2007, if the
11 oocytes were donated pursuant to protocols or standards that are
12 generally recognized and accepted by national or international
13 scientific bodies.

14 (d) Any written document required pursuant to this section
15 shall adhere to simplified reading standards, including, but not
16 limited to, those generally accepted and required for government
17 publications, and in layperson's language. The document shall be
18 made available in languages spoken by subjects in the study if
19 their proficiency is largely in a language other than English. All
20 information in the written informed consent document shall also
21 be conveyed to the subject orally in easy to understand and
22 nontechnical terms.

23 125341. An institutional review board (IRB) that reviews and
24 approves medical and scientific research shall require all of the
25 following of any research program or project that comes under its
26 review that involves AOP or any alternative method of oocyte
27 retrieval:

28 (a) That it include a written summary as required under
29 Section 125335 that would include information on health risks
30 and potential adverse consequences of the procedure and
31 describe the manner in which the subject will receive and review
32 this written summary.

33 (b) That it obtain informed consent in compliance with the
34 Protection of Human Subjects in Medical Experimentation Act
35 (Chapter 1.3 (commencing with Section 24170) of Division 20),
36 including informed consent for information obtained pursuant to
37 Section 125342.

38 (c) That it provide the subject with an objective and accurate
39 statement about the existing state of the research for which the
40 subject is providing oocytes.

1 (d) That it perform psychological and physical screening, in
2 accordance with the appropriate standard of care, for all subjects
3 prior to the oocyte retrieval procedure.

4 (e) That it ensure that after conducting AOP or any alternative
5 method of oocyte retrieval on a subject, the subject be given a
6 postprocedure medical examination at a time within the standard
7 of care to determine if the subject has experienced an adverse
8 health effect that is a result of the procedure. The subject shall be
9 informed that she has the right to a second opinion if she has any
10 medical concerns.

11 (f) That it ensure that the subject has access to and coverage
12 for medically appropriate medical care that is required as a direct
13 result of the procedure for research purposes. The research
14 program or project shall ensure that payment or coverage of
15 resulting medical expenses be provided at no cost to the subject
16 and that a summary of the arrangements the procuring entity has
17 made for coverage or payment for medical care related to AOP or
18 any alternative method of oocyte retrieval is provided to the
19 subject prior to the procedure.

20 (g) That it provide a summary informing the subject that
21 oocytes may not be sold or transferred for valuable consideration
22 except as set forth in Section 125350.

23 (h) That it provide disclosure if the physician and surgeon and
24 his or her immediate family members have any professional
25 interest in the outcome of the research or of the oocyte retrieval
26 procedure and, if so, that it provide disclosure that he or she
27 carries the interest of both the subject and the success of the
28 research.

29 125342. (a) A research program or project that involves AOP
30 or any alternative method of oocyte retrieval shall ensure that a
31 written record is established and maintained to include, but not
32 be limited to, all of the following components:

33 (1) The demographics of subjects, including, but not limited
34 to, their age, race, primary language, ethnicity, income bracket,
35 education level, and the first three digits of the ZIP Code of
36 current residence.

37 (2) Information—*of regarding* every oocyte that has been
38 donated or used. This record should be sufficient to determine the
39 provenance and disposition of those materials.

1 (3) A record of all adverse health outcomes, including, but not
2 limited to, incidences and degrees of severity, resulting from the
3 AOP or any alternative method of oocyte retrieval.

4 (b) (1) The information included in the written record
5 pursuant to subdivision (a) shall not disclose personally
6 identifiable information about subjects, and shall be confidential
7 and is deemed protected by subject privacy provisions of law.
8 This information shall be reported to ~~the Maternal, Child, and~~
9 ~~Adolescent Health Branch~~ of the State Department of Health
10 Services, which shall aggregate the data and make it publicly
11 available, *as set forth in paragraph (2)*, in a manner that does not
12 reveal personally identifiable information about the subjects.

13 (2) *The department shall provide public access to information*
14 *which it is required to release pursuant to the California Public*
15 *Records Act (Chapter 3.5 (commencing with Section 6250) of*
16 *Division 7 of Title 1 of the Government Code). The department*
17 *shall disseminate the information to the general public via*
18 *governmental and other Web sites in a manner that is*
19 *understandable to the average person. The information shall be*
20 *made available to the public when the biennial review pursuant*
21 *to Section 125119.5 is provided to the Legislature.*

22 125343. Any employee who works in the unit conducting
23 stem cell research using human oocytes, persons who report to,
24 or are supervised by, the principal investigator or key personnel
25 of the project, or both, along with the principal investigator and
26 the key personnel of the project, and the immediate family
27 members of any of the above persons are prohibited from being a
28 subject in the research.

29 125344. The physician and surgeon performing the AOP or
30 any alternative method of oocyte retrieval shall not have a
31 financial interest in the outcome of the research.

32 125345. Pursuant to guidelines adopted by the Research
33 Council and Institute of Medicine of the National Academies,
34 researchers shall offer subjects an opportunity to document their
35 preferences regarding future uses of their donated materials. The
36 consent process shall fully explore whether subjects have
37 objections to any specific forms of research to ensure that their
38 wishes are honored.

39 125346. Any procedures for procuring oocytes in this state
40 for research or the development of medical therapies shall meet

1 all of the standards for subjects included in this chapter. All
2 oocytes procured outside of this state for research taking place in
3 this state shall meet these same standards. All egg extractions for
4 research shall be approved by an institutional review board
5 pursuant to Section 125341.

6 125350. No human oocyte or embryo shall be acquired, sold,
7 offered for sale, received, or otherwise transferred for valuable
8 consideration for the purposes of medical research or
9 development of medical therapies. For purposes of this section,
10 “valuable consideration” does not include reasonable payment
11 for the removal, processing, disposal, preservation, quality
12 control, and storage of oocytes or embryos.

13 125355. No payment in excess of the amount of
14 reimbursement of direct expenses incurred as a result of the
15 procedure shall be made to any ~~research~~ subject to encourage her
16 to produce human oocytes for the purposes of medical research.

17 SEC. 8. This act shall not be construed to amend Proposition
18 71, approved by the voters at the November 2, 2004, general
19 election.